Discriminative functional connectivity signature of cocaine use disorder links to rTMS treatment response.

Autor: Zhao K; Department of Bioengineering, Lehigh University, Bethlehem, PA, USA., Fonzo GA; Center for Psychedelic Research and Therapy, Department of Psychiatry and Behavioral Sciences, Dell Medical School, The University of Texas at Austin, Austin, TX, USA., Xie H; Center for Neuroscience Research, Children's National Hospital, Washington DC, USA.; George Washington University School of Medicine, Washington DC, USA., Oathes DJ; Center for Neuromodulation in Depression and Stress, Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Keller CJ; Wu Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA., Carlisle NB; Department of Psychology, Lehigh University, Bethlehem, PA, USA., Etkin A; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.; Alto Neuroscience, Los Altos, CA, USA., Garza-Villarreal EA; Instituto de Neurobiología, Universidad Nacional Autónoma de México campus Juriquilla, Querétaro, Mexico., Zhang Y; Department of Bioengineering, Lehigh University, Bethlehem, PA, USA.; Department of Electrical and Computer Engineering, Lehigh University, Bethlehem, PA, USA.
Jazyk: angličtina
Zdroj: Nature. Mental health [Nat Ment Health] 2024 Apr; Vol. 2 (4), pp. 388-400. Date of Electronic Publication: 2024 Feb 16.
DOI: 10.1038/s44220-024-00209-1
Abstrakt: Cocaine use disorder (CUD) is prevalent, and repetitive transcranial magnetic stimulation (rTMS) shows promise in reducing cravings. However, the association between a consistent CUD-specific functional connectivity signature and treatment response remains unclear. Here we identify a validated functional connectivity signature from functional magnetic resonance imaging to discriminate CUD, with successful independent replication. We found increased connectivity within the visual and dorsal attention networks and between the frontoparietal control and ventral attention networks, alongside reduced connectivity between the default mode and limbic networks in patients with CUD. These connections were associated with drug use history and cognitive impairments. Using data from a randomized clinical trial, we also established the prognostic value of these functional connectivities for rTMS treatment outcomes in CUD, especially involving the frontoparietal control and default mode networks. Our findings reveal insights into the neurobiological mechanisms of CUD and link functional connectivity biomarkers with rTMS treatment response, offering potential targets for future therapeutic development.
Competing Interests: G.A.F. received monetary compensation for consulting work for SynapseBio AI and owns equity in Alto Neuroscience. A.E. reports salary and equity from Alto Neuroscience and holds equity in Akili Interactive and Mindstrong Health. The other authors declare no competing interests.
Databáze: MEDLINE
Externí odkaz: